Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alexion Pharmaceuticals ( ALXN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.3%. By the end of trading, Alexion Pharmaceuticals rose $2.91 (1.9%) to $157.40 on average volume. Throughout the day, 1,237,176 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,213,000 shares. The stock ranged in a price between $153.72-$157.59 after having opened the day at $154.33 as compared to the previous trading day's close of $154.49. Other companies within the Health Care sector that increased today were: Prima Biomed ( PBMD), up 45.3%, Misonix ( MSON), up 16.7%, Repros Therapeutics ( RPRX), up 15.8% and Biolase ( BIOL), up 13.9%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $30.6 billion and is part of the drugs industry. Shares are up 17.6% year to date as of the close of trading on Wednesday. Currently there are 17 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Oramed Pharmaceuticals ( ORMP), down 13.8%, DARA Biosciences ( DARA), down 13.8%, GW Pharmaceuticals ( GWPH), down 9.4% and Pernix Therapeutics Holdings ( PTX), down 9.3% , were all laggards within the health care sector with AstraZeneca ( AZN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk